Cosentyx: how was the first human dose set?
secukinumab · IL-17A
First-in-human starting dose
Not stated in public reviews
Why it's blank
The public FDA and EMA reviews of Cosentyx don't say how the first human dose was chosen. That rationale is in the IND, which is confidential, so it is missing for most approved products.
How it's usually set for monoclonal antibodies outside oncology
Find the highest dose with no adverse effects (NOAEL) in each animal species, convert it to a human equivalent dose, usually by body surface area, pick the most appropriate species, then divide by a safety factor (default 10) to get the maximum recommended starting dose.
“In general, one should consider using a safety factor of at least 10. The MRSD should be obtained by dividing the HED by the safety factor.”
This product's starting point
NOAEL / key findings: NOAEL 50 mg/kg/week in monkey repeat-dose studies, based on clinical chemistry effects and immunotoxicity (lymphocyte, B- and T-cell decreases) at high dose (FDA pharmacology/toxicology review, p. 7)
NOAEL / key findings
NOAEL 50 mg/kg/week in monkey repeat-dose studies, based on clinical chemistry effects and immunotoxicity (lymphocyte, B- and T-cell decreases) at high dose
“Due to clinical chemistry effects and immunotoxicity (decreases in total lymphocytes, B cells and T cells) observed at the high dose, the NOAEL appears to be 50 mg/kg/week.”
Same question, other monoclonal antibodies
Single-dose clinical escalation supported by monkey AUC margin: 10 mg/kg AUC ~50,000 µg·hr/mL vs human AUC 10,000 at 114 mg
Cinqair
reslizumab · IL-5Phase 1 single-dose escalation in severe asthma at 0.03 to 1.0 mg/kg; derivation of starting dose not described
Danyelza
naxitamab · GD2Initial trials based on prior clinical data with the murine parent antibody, not on toxicology data with naxitamab
Imaavy
nipocalimab · FcRnFirst-in-human SAD in healthy volunteers started at 0.3 mg/kg IV, escalating to 60 mg/kg; derivation not stated
Rituxan
rituximab · CD20Based on monkey pilot study relating multiple-dose rituximab exposure to B-cell depletion
Sarclisa
isatuximab · CD38MABEL and in vitro receptor occupancy: 0.0001 mg/kg, about 10% predicted CD38 occupancy in B and T cells
Actemra
tocilizumab · IL-6RNot stated in public reviews
Adakveo
crizanlizumab · P-selectinNot stated in public reviews
Adbry
tralokinumab · IL-13Not stated in public reviews
Aduhelm
aducanumab · Aggregated amyloid-βNot stated in public reviews
Aimovig
erenumab · CGRP receptorNot stated in public reviews
Ajovy
fremanezumab · CGRPNot stated in public reviews
Alhemo
concizumab · TFPINot stated in public reviews
Andembry
garadacimab · Factor XIIaNot stated in public reviews
Arzerra
ofatumumab · CD20Not stated in public reviews
Avastin
bevacizumab · VEGF-ANot stated in public reviews
Bavencio
avelumab · PD-L1Not stated in public reviews
Benlysta
belimumab · BLyS (BAFF)Not stated in public reviews
Beovu
brolucizumab · VEGF-ANot stated in public reviews
Beyfortus
nirsevimab · RSV F proteinNot stated in public reviews
Bimzelx
bimekizumab · IL-17A/IL-17FNot stated in public reviews
Briumvi
ublituximab · CD20Not stated in public reviews
Cablivi
caplacizumab · von Willebrand factor (A1 domain)Not stated in public reviews
Campath
alemtuzumab · CD52Not stated in public reviews
Cimzia
certolizumab pegol · TNF-αNot stated in public reviews
Crysvita
burosumab · FGF23Not stated in public reviews
Cyramza
ramucirumab · VEGFR2Not stated in public reviews
Darzalex
daratumumab · CD38Not stated in public reviews
Dupixent
dupilumab · IL-4RaNot stated in public reviews
Ebanga
ansuvimab · Zaire ebolavirus glycoproteinNot stated in public reviews
Ebglyss
lebrikizumab · IL-13Not stated in public reviews
Emgality
galcanezumab · CGRPNot stated in public reviews
Empliciti
elotuzumab · SLAMF7Not stated in public reviews
Enflonsia
clesrovimab · RSV F protein (site IV)Not stated in public reviews
Enjaymo
sutimlimab · Complement C1sNot stated in public reviews
Enspryng
satralizumab · IL-6RNot stated in public reviews
Entyvio
vedolizumab · α4β7-integrinNot stated in public reviews
Erbitux
cetuximab · EGFRNot stated in public reviews
Evenity
romosozumab · SclerostinNot stated in public reviews
Evkeeza
evinacumab · ANGPTL3Not stated in public reviews
Exdensur
depemokimab · IL-5Not stated in public reviews
Fasenra
benralizumab · IL-5RαNot stated in public reviews
Gamifant
emapalumab · IFN-γNot stated in public reviews
Gazyva
obinutuzumab · CD20Not stated in public reviews
Herceptin
trastuzumab · HER2Not stated in public reviews
Humira
adalimumab · TNF-αNot stated in public reviews
Hympavzi
marstacimab · TFPINot stated in public reviews
Ilaris
canakinumab · IL-1βNot stated in public reviews
Ilumya
tildrakizumab · IL-23 p19Not stated in public reviews
Imfinzi
durvalumab · PD-L1Not stated in public reviews
Imjudo
tremelimumab · CTLA-4Not stated in public reviews
Jemperli
dostarlimab · PD-1Not stated in public reviews
Kevzara
sarilumab · IL-6RNot stated in public reviews
Keytruda
pembrolizumab · PD-1Not stated in public reviews
Kisunla
donanemab · Amyloid-β (N3pG)Not stated in public reviews
Lartruvo
olaratumab · PDGFRαNot stated in public reviews
Leqembi
lecanemab · Amyloid-β protofibrilsNot stated in public reviews
Libtayo
cemiplimab · PD-1Not stated in public reviews
Loqtorzi
toripalimab · PD-1Not stated in public reviews
Lucentis
ranibizumab · VEGF-ANot stated in public reviews
Margenza
margetuximab · HER2Not stated in public reviews
Monjuvi
tafasitamab · CD19Not stated in public reviews
Nemluvio
nemolizumab · IL-31RANot stated in public reviews
Niktimvo
axatilimab · CSF-1RNot stated in public reviews
Nucala
mepolizumab · IL-5Not stated in public reviews
Ocrevus
ocrelizumab · CD20Not stated in public reviews
Omvoh
mirikizumab · IL-23 p19Not stated in public reviews
Opdivo
nivolumab · PD-1Not stated in public reviews
Pasatru
garetosmab · Activin ANot stated in public reviews
Penpulimab
penpulimab · PD-1Not stated in public reviews
Perjeta
pertuzumab · HER2Not stated in public reviews
Piasky
crovalimab · Complement C5Not stated in public reviews
Portrazza
necitumumab · EGFRNot stated in public reviews
Poteligeo
mogamulizumab · CCR4Not stated in public reviews
Praluent
alirocumab · PCSK9Not stated in public reviews
Praxbind
idarucizumab · DabigatranNot stated in public reviews
Prolia
denosumab · RANKLNot stated in public reviews
Raxibacumab
raxibacumab · B. anthracis protective antigenNot stated in public reviews
Remicade
infliximab · TNF-αNot stated in public reviews
Repatha
evolocumab · PCSK9Not stated in public reviews
Rystiggo
rozanolixizumab · FcRnNot stated in public reviews
Saphnelo
anifrolumab · IFNAR1Not stated in public reviews
Siliq
brodalumab · IL-17RANot stated in public reviews
Simponi
golimumab · TNF-αNot stated in public reviews
Simulect
basiliximab · IL-2Rα (CD25)Not stated in public reviews
Skyrizi
risankizumab · IL-23 p19Not stated in public reviews
Soliris
eculizumab · Complement C5Not stated in public reviews
Spevigo
spesolimab · IL-36RNot stated in public reviews
Stelara
ustekinumab · IL-12/23 p40Not stated in public reviews
Sylvant
siltuximab · IL-6Not stated in public reviews
Synagis
palivizumab · RSV F proteinNot stated in public reviews
Takhzyro
lanadelumab · Plasma kallikreinNot stated in public reviews
Taltz
ixekizumab · IL-17ANot stated in public reviews
Tecentriq
atezolizumab · PD-L1Not stated in public reviews
Tepezza
teprotumumab · IGF-1RNot stated in public reviews
Tevimbra
tislelizumab · PD-1Not stated in public reviews
Tezspire
tezepelumab · TSLPNot stated in public reviews
Tremfya
guselkumab · IL-23 p19Not stated in public reviews
Trogarzo
ibalizumab · CD4Not stated in public reviews
Tysabri
natalizumab · α4-integrinNot stated in public reviews
Tzield
teplizumab · CD3Not stated in public reviews
Ultomiris
ravulizumab · Complement C5Not stated in public reviews
Unituxin
dinutuximab · GD2Not stated in public reviews
Unloxcyt
cosibelimab · PD-L1Not stated in public reviews
Uplizna
inebilizumab · CD19Not stated in public reviews
Vectibix
panitumumab · EGFRNot stated in public reviews
Veopoz
pozelimab · Complement C5Not stated in public reviews
Voyxact
sibeprenlimab · APRILNot stated in public reviews
Vyepti
eptinezumab · CGRPNot stated in public reviews
Vyloy
zolbetuximab · Claudin 18.2Not stated in public reviews
Xolair
omalizumab · IgENot stated in public reviews
Yartemlea
narsoplimab · MASP-2Not stated in public reviews
Yervoy
ipilimumab · CTLA-4Not stated in public reviews
Zinbryta
daclizumab · IL-2Rα (CD25)Not stated in public reviews
Zinplava
bezlotoxumab · C. difficile toxin BNot stated in public reviews
Zynyz
retifanlimab · PD-1Not stated in public reviews